{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000024","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.137597+00:00","generated_at":"2026-06-05T06:03:01.397349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ANI Pharmaceuticals Q4 revenue up 39.7% YoY; issues 2024 guidance with Cortrophin Gel growth 52-61%","bullets":["Q4 net revenues $131.7M (+39.7% YoY); GAAP diluted EPS $0.04; adjusted non-GAAP diluted EPS $1.00.","Rare Disease (Cortrophin Gel) Q4 revenue $41.7M (+137.3% YoY) with record new patient starts and prescribers.","Full-year 2023 net revenue $486.8M, adjusted EBITDA $133.8M, operating cash flow $119.0M.","2024 guidance: net revenue $520-542M, Cortrophin Gel $170-180M, adjusted EBITDA $135-145M, adjusted EPS $4.26-$4.67.","Generics segment revenue $71.8M (+23.8% YoY); 11 new products launched in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000024","json":"https://secwatch.observer/filing/0001023024-24-000024.json","markdown":"https://secwatch.observer/filing/0001023024-24-000024.md","text":"https://secwatch.observer/filing/0001023024-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/0001023024-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/ani-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:03:01.397349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a493c5e5aa1ca4fbbbe1b821b85695cf81f0285f","claim":"ANI PHARMACEUTICALS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $131.7 million, net income $0.7 million, EPS $0.04. Guidance initiated.","evidence_excerpt":"ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance • Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/0001023024-24-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$131.7 million"},{"label":"Net income","value":"$0.7 million"},{"label":"EPS","value":"$0.04"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}